St. Jude Medical, Inc. (NYSE: STJ) today announced it will unveil its new corporate identity to physician customers at the 88th Annual Meeting of the American Association of Thoracic Surgery (AATS) on May 10, at EuroPCR on May 13 and at the Heart Rhythm Society's (HRS) Annual Scientific Sessions on May 14. The new brand identity is designed to communicate the company's mission to develop medical technology and services that put more control into the hands of those who treat cardiac, neurological and chronic pain patients, worldwide.

"Customers count on us to help them attain the best possible patient outcomes by reducing as much risk as possible,? said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. ?This priority drives our innovation, our quality program, our clinical studies and our new product introductions. It has been a critical element of our success and makes us a different kind of partner for physicians.?

As a part of the brand identity, the new St. Jude Medical logo consists of eight small squares organized into a larger square, with an unaligned 9th square in the middle. The unaligned, center element represents the risks that are present in any medical procedure, while the organized exterior box represents the company's commitment to helping physicians control those risks.

?Since our origins in 1976, we have focused on the quality, safety and reliability of our devices,? said Starks. ?Our new brand identity better symbolizes the intensity of our focus and our commitment to providing physicians with the medical technology and services they need to control risks wherever possible.?

Over the past several years, St. Jude Medical has made significant investments in each of the company's product areas that reflect its commitment and mission. These innovations include the following:

  • The ?Unity? device platform; a comprehensive technology platform for all new pacemakers, ICDs, and CRT devices, which enables St. Jude Medical to update new features and diagnostic tools through software as they become available. As part of its risk-reduction focus, the Unity platform allows for remote patient monitoring and has system integrity checks, vibratory patient notification and ?triple redundant? safety features that provide automatic back-ups for life-saving therapies.
  • The industry's most advanced lead offerings, including the Durata? 7 F high voltage lead, which features dual redundant cables for back-up protection. The Durata lead's Optim® insulation – a hybrid insulation material unique to St. Jude Medical – blends the biostability and flexibility of high-performance silicone rubber with the strength, tear resistance and abrasion resistance of polyurethane to provide increased durability and flexibility. In addition, the Durata features a soft silicone tip with a larger surface area and a slightly-curved right ventricle shock coil, intended to enhance ease of use and handling for implanting physicians.
  • Therapies dedicated to curing abnormal heart rhythms, such as atrial fibrillation. Recent advancements for treating cardiac arrhythmias include advanced, irrigated RF ablation systems and enhanced cardiac imaging with the EnSite System and its EnSite Fusion? Registration Module, which provides physicians with highly detailed views of the heart's anatomy. Together, these and similar advancements help physicians better diagnose arrhythmias and guide the delivery of therapy, to help physicians achieve the best possible patient outcomes.
  • A comprehensive portfolio of neurostimulation products including Eon Mini?, the world's smallest and longest-lasting spinal cord stimulator in its class for chronic pain. Physicians have more control in configuring a system to address the patient's individual pain patterns by choosing from a broad selection of generators, extensive lead options and advanced programming capabilities. Beyond chronic pain, clinical trials are underway for depression, migraine headache, Parkinson's disease, essential tremor and other conditions.
  • A broad portfolio of surgical products for treating heart valve disease, including the Epic? Stented Tissue Valve with Linx? AC Technology – a patented, proprietary anti-calcification treatment designed to enhance the valve's durability.
  • Cardiology products including the leading vascular closure device – Angio-Seal – of which more than 11 million devices have been sold. Its most recent advancement, Angio-Seal VIP, is designed for use in both diagnostic procedures as well as the most challenging interventional procedures.

As a part of the re-branding, the company's Web site, www.sjm.com is also undergoing a redesign. Portions of the new site are already active, and St. Jude Medical will continue to update other areas of the site over the coming months.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 12,000 people worldwide and has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. For more information, please visit www.sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings, and market shares. The statements made by the Company are based upon management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company's control and the risk factors and other cautionary statements described in the Company's filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company's Annual Report on Form 10-K filed on February 27, 2008. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

St. Jude Medical, Inc.
Investor Relations
Angela Craig, 651-481-7789
or
Media Relations
Kathleen Janasz, 651-415-7042